Adam S. Grossman - Feb 19, 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: President and CEO, Director
Signature: /s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact
Stock symbol: ADMA
Transactions as of: Feb 19, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/21/2025, 09:01 PM
Previous filing: Jan 3, 2025
Next filing: Feb 27, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Award	$0	+252K	+12.76%	$0.00	2.23M	Feb 19, 2025	Direct	F1, F2, F3, F4
holding	ADMA	Common Stock						1.14M	Feb 19, 2025	See Footnote	F5
holding	ADMA	Common Stock						581K	Feb 19, 2025	See Footnote	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Stock Option (right to buy)	Award	$0	+377K		$0.00	377K	Feb 19, 2025	Common Stock	377K	$16.07	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.
F2	Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F3	(continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;
F4	(continued from footnote 3) and (vi) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F5	These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
F6	These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
F7	The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan.